We provide clients with a one-stop customized service, from target analysis and molecular design to experimental validation, covering de novo design and targeted modification of peptide drugs, antigens and antibodies, and functional proteins. This service is nearly 50 times more efficient than traditional manual design, and the delivered molecules possess 100% independent intellectual property rights. Our independently developed GLP-1 receptor agonist pipeline has a half-life 2.8 times that of smegglutide.

Deeply integrating artificial intelligence and high-performance computing technologies, this platform provides biopharmaceutical and synthetic biology companies with digital tools covering sequence generation, structure prediction, and functional screening. It integrates a self-developed algorithm matrix, supports graphical drag-and-drop operation and one-click automated processes, allowing users to efficiently design and virtually screen protein molecules without writing code, quickly identifying highly active and stable candidate molecules.

Integrating directed evolution, rational computation, and artificial intelligence technologies, we provide de novo design and directed modification of high-performance enzymes for clients in the industrial catalysis and biopharmaceutical fields. This service overcomes the bottleneck of traditional enzyme modification relying on extensive experimental screening. Based on our self-developed algorithms, we achieve synergistic optimization of sequence, structure, and function, successfully obtaining multiple new sequences with higher activity than natural enzymes in projects already delivered to marketed pharmaceutical companies.